medigraphic.com
ISSN 1025-0255 (Electronic)

2015, Number 3

<< Back Next >>

AMC 2015; 19 (3)

Long QT syndrome and sudden cardiovascular death

Carreras CF, Castellanos RR, Perozo PR, Ramírez LL

Language: Spanish
References: 34
Page: 279-287
PDF size: 494.85 Kb.


ABSTRACT

Background: long QT syndrome is an arrhythmogenic canalopathy characterized by a serious alteration in the ventricular repolarization, translated electrocardiographically by a prolongation of the QT interval that predispose to sudden death caused by malignant ventricular arrhythmias tracing in torsades de pointes.
Objective: to present the clinical case of a patient with this syndrome that is infrequent in our environment.
Clinical case: a thirty-one-year-old patient with antecedents of being a healthy person, who was admitted in the hospital twice during her pregnancy because of high arterial pressure in 2013. The patient presented syncope manifestations from which she recovered spontaneously. In January 2014, the patient is admitted in the hospital with dyspeptic disorders and epigastralgia. After being admitted, the patient presented syncope manifestations and ventricular tachycardia exhibited on the electrocardiogram tracing in torsades de pointes and cardiac arrest. It was necessary to perform a cardiopulmonary resuscitation and endotracheal intubation. The patient presented this combination of manifestations for 48 hours. She is sent to the Cardiology Institute of Havana where she is studied by the arrhythmia medical team and the implantation of an implantable cardioverter-defibrillator is decided.


REFERENCES

  1. Van den Branden B, Wever E, Boersma L. Torsade de pointes with short coupling in-terval. Acta Cardiol. 2010;65(3):345-6.

  2. Smith DS. Is long QT síndrome a disease of abnormal mechanical contraction. Circ Arrhythm Electrophysiol. 2010;122(8):1353-54.

  3. De Jesús Pérez VA, Haddad F, Vagelos RH, Fearon W, Feinstein J, Zamanian RT. Angi-na associated with left main coronary ar-tery compression in pulmonary hyperten-sion. J Heart Lung Transplant. 2009;28(5):527-30.

  4. Tseng PT, Lee Y, Lin YE, Lin PY. Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: A case report and literature review. Gen Hosp Psychiatry. 2012;34(210):13-15.

  5. Deshmukh A, Ulveling K, Alla V, Abuissa H, Airey K. Prolonged QTc interval and tor-sades de pointes induced by citalopram. Tex Heart Inst J. 2012;39(1):68-70.

  6. FDA Drug Safety Comunication [Internet]. 2012 Mar 28 [citado 23 Abr 2014]. Dispo-nible en: http://www.fda.gov/Drugs/DrugsSafety/ucm297391.htm

  7. Howland RH. A critical evaluation of the cardiac toxicity of citalopram: Part1. J Psy-chosoc Nurs Ment Health Serv. 2011;49(2):13-6.

  8. Van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med. 2009;54(8):404-8.

  9. Castro Ferman VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, et al. QT interval and antidepressant use: A cross sectional study of electronichealth records. BMJ. 2013;29(1):346.

  10. Zivin K, Pfeiffer PN, Bohnert AS, Ganoczy D, Blow FC, Nallamothu BK, et al. Evalua-tion of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry. 2013;170(6):642-50.

  11. Jiménez Candil J, González Matas JM, Cruz González I, Hernández Hernández J, Martín Diaz A, Pabón Andres P, et al. Pronóstico hospitalario del síndrome Coronario agudo sin elevación Del segmento ST determina-do por una nueva escala de riesgo integra-da por variables electrocardiográficas ob-tenidas al ingreso. Rev Esp Cardiol. 2010;63(7):851-5.

  12. Yilmaz MB, Yontar C, Erdem A, Karadas F, Yalta K, Turgut OO, et al. Comparative ef-fects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure. Heart Vessels. 2009;24(5):16-21

  13. Wong JA, Gula LJ, Klein GJ, Yee R, Skanes AC, Krahn AD. Utility of tradmilltesting in identification and genotype prediction in Long-QT Syndrome. Circ Arrhythm Elec-trophydiol. 2010;3(3):120-25.

  14. Drezner JA, Ackerman MJ, Cannon BC, Corrado D, Heidbuchel H, Prutkin JM, et al. Abnormal electrocardiographic findings in athletes: recognising changes suggestive of primary electrical disease. Br J Sports Med. 2013;47(3):153-67.

  15. Chattha IS, Sy RW, Yee R, Gula LJ, Snakes AC, Klein GJ, et al. Utility of the 16-Shimizu W. Diagnosis Evaluation of Long QT Syndrome. Card Electroph Clin. 2012;4(8):29-37.

  16. Viskin S, Belhassen B, Wilde AA. Irreplace-able antiarrhythmic medications are disap-pearing: the case of Quinidine. Heart Rhythm. 2010;7(1):863.

  17. Haissaguerre M, Sacher F, Nogami A, Ko-miya N, Bernard A, Probst V, et al. Charac-teristics of recurrent ventricular fibrillation associated with inferolateral early repolari-zation. J Am Coll Cardiol. 2009;53(3):612-9.

  18. Antzelevitch C, Yan GX. J wave syn-dromes. Heart Rhythm. 2010;7:549-58.

  19. Viskin S. Idiopathic ventricular fibrilla-tion. “Le síndrome d’ Haissaguerre” and the fear of J waves. J Am Coll Cardiol. 2009;53(4):620-2.

  20. Ghosh S, Cooper DH, Vijayakumar R, Zhang J, Pollak S, Haissaguerre M, et al. Early repolarization associated with sudden death: insights from noninvasive electro-cardiographic imaging. Heart Rhythm. 2010;7(5):534-7.

  21. Márquez Diaz MF. El síndrome de QT largo: una breve revisión del diagnóstico electro-cardiográfco incluyendo la prueba de Vis-kin. Arch Cardiol Mex. 2012;82(3):243-7.

  22. Jiang W, Velazquez Guedez EJ, Kuchibhatla M, Samad Z, Boyle SH, Kuhn C, et al. Ef-fect of escitalopram on mental stress-induced myocardial ischemia:Results of the REMIT trial. JAMA. 2013;309(1):2139-49.

  23. Venetucci L, Denegri M, Napolitano C, Priori SG. Inherited calcium channelopathies in the pathophysiology of arrhythmias. Nat Rev Cardiol. 2012;9(2):561–75.

  24. Van der Werf C, Nederend I, Hofman N. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: dis-ease penetrance and expression in cardiac ryanodine receptor mutation-carrying rela-tives. Circ Arrhythm Electrophysiol. 2012;5(6):748–56.

  25. Watanabe H, Chopra N, Laver D. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and hu-mans. Nat Med. 2009;15:380–3.

  26. Zayas molina R. Actualización sobre el sín-drome de QT largo congénito. Rev Cubana Invest Bioméd. 2012;31(2):34-56.

  27. Chávez González E. El Intervalo QT, su ori-gen e importancia del conocimiento de fór-mulas para su medición en diferentes cir-cunstancias clínicas. Cor Salud. 2014;6(1):34-40.

  28. Hong RA, Jittirat A, Choi JJ. Flecainide sup-presses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2012;359(3):794–7.

  29. Kimura H, Zhou J, Kawamura M. Phenotype variability in patients carrying KCNJ2 muta-tions. Circ Cardiovasc Genet. 2012;5:344–53.

  30. Faggioni M, Knollmann BC. Calsequestrin 2 and arrhythmias. Am J Physiol Heart Circ Physiol. 2012;302(3):H1250–H1256.

  31. Priori SG, Chen SR. Inherited dysfunction of sarcoplasmic reticulum Ca2 þ handling and arrhythmogenesis. Circ Res. 2011;108(1):871–83.

  32. Ruesta Casote V. Una forma atípica de sín-drome de QT largo: Heraldos de muerte súbita cardíaca. Gac Méd Caracas [Internet]. Mar 2008 [citado 12 Jun 2014];116(1):[aprox. 6 p.]. Disponible en: http://www.scielo.org.ve/scielo.php?script=sci_arttext&pid=S0367-47622008000100007&lng=es.

  33. Características clínicas, pronóstico vital y funcional de los pacientes supervivientes a una muerte súbita extrahospitalaria ingre-sados en cinco unidades de cuidados inten-sivos cardiológicos. Rev Esp Cardiol. 2013;66(2):623-8.

  34. Ochoa Montes LA, González Lugo M. Epi-demiología de la muerte súbita cardíaca. Rev Cubana Hig Epidemiol. 2012;50(1):23-34.




2020     |     www.medigraphic.com